The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

In a huge new statistical analysis, researchers have found more evidence than ever that drugs like Ozempic can help curb ...

We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Research published in the journal Addiction indicates that GLP-1 drugs like Ozempic may play a crucial role in reducing ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

The Beijing IP Court’s decision to revive a key semaglutide patent based on experimental data has far-reaching legal and ...

We recently compiled a list of the 10 Most Promising Future Stocks According to Analysts. In this article, we are going to ...

A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in ...